Home
overview
Drug delivery has become increasingly important in today’s highly competitive market. The rise of patient empowerment and the spiralling R & D costs have impacted on the image of drug delivery systems within the pharmaceutical industry. Novel systems can be used to revitalise a compound when issues of safety have forced the development to be halted and can also increase the economic attractiveness of a compound to the healthcare payers. This climate of change presents huge commercial opportunities for the drug delivery industry.

As a senior pharmaceutical or drug delivery executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for SMi’s 4th Annual Conference Drug Delivery Systems: Exploiting Commercial Opportunities. As you will see from the brochure, key speakers include representatives from both the pharmaceutical and drug delivery industry.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Christi Mitchell

Christi Mitchell, Director, Medius

9:10 STRATEGIES OF DRUG DELIVERY AND PHARMA COMPANIES: CONFLICTS AND ALIGNMENTS

Dr Gordon Findlay

Dr Gordon Findlay, Business Projects Manager, CMR International

  • The true status of the pharmaceutical industry in developing and marketing drug delivery technology world-wide
  • Major issues in the pharmaceutical industry that limit the application of drug delivery systems
  • A focus on the benefits and difficulties of collaborations between drug delivery and pharmaceutical companies, based on companies’ experiences in collaborative projects to date
  • Different strategies for identification and evaluation of drug delivery technologies and structuring collaborations
  • 9:40 PRODUCT DEVELOPMENT USING DRUG DELIVERY

    Jon Watts

    Jon Watts, Director, Business Development, Powderject

  • Using drug delivery to enhance a product
  • Choosing the optimum systems
  • Valuing delivery systems
  • Benefits that can be gained through delivery systems
  • Extending patent life using novel drug delivery systems
  • 10:20 THE CHANGING MARKET

    Lewis Bender

    Lewis Bender, Senior Vice President, Business Development, Emisphere Technologies

  • Overview of market changes in the pharmaceutical industry
  • Drug delivery systems and extending patent life
  • Impact of biotechnology on drug delivery methods
  • Patient empowerment and the need for better delivery methods
  • Increasing importance of pharmacoeconomics
  • Increasing collaborations and outsourcing within the pharmaceutical industry
  • 11:00 Morning Coffee

    11:20 KNOLL: SOLID SOLUTIONS FOR INSOLUBLE SUBSTANCES

    Dr Joerg Breitenbach

    Dr Joerg Breitenbach, Director Product & Technological Development Extrusion, Knoll

  • Solid solutions via an integrated system: Melt Extrusion
  • Polymorphism and its impact on drug development
  • A breakthrough in Nanoparticle Technology: NanoMorph
  • 12:00 INHALE THERAPEUTICS: BUSINESS TARGETS

    Dr Christopher Searcy

    Dr Christopher Searcy, Vice President, New Business Opportunities, Inhale Therapeutic Systems

  • What are Inhaleables?
  • Technical considerations in choosing a partner
  • IP considerations, look before you leap!
  • Examples of Inhaleable products in development today
  • What determine a good commercial opportunity in this area?
  • What will the future hold for this category of drug delivery?
  • 12:40 Lunch

    14:00 INTRAJECT: CHOOSING THE CORRECT DRUG DELIVERY TECHNOLOGY

    Khawar Mann

    Khawar Mann, Director, Business Development, Weston Medical

  • Overview of Weston Medical and INTRAJECT
  • Choosing the right opportunity: commercial and technology considerations
  • Risk Return Profile
  • Life cycle management: NCE’s, off-patent
  • 14:40 GENE DELIVERY SYSTEMS

    Martin Nash

    Martin Nash, Chief Executive Officer, Genetronics

  • Potential market for gene delivery systems
  • Technical hurdles in the hunt for effective gene delivery systems
  • Partnership opportunities with the pharmaceutical industry
  • Marketing and patient acceptance issues for gene therapy
  • Future directions for the drug delivery industry in the gene therapy arena
  • 15:20 Afternoon Tea

    15:40 EVALUATING DRUG DELIVERY TECHNOLOGY

    Dr Susan Scott

    Dr Susan Scott, Project Director, SmithKline Beecham

  • Effective market research
  • Developing the big picture: Target Product Profile
  • Choice of drug delivery partner
  • Making the alliance mutually successful
  • 16:20 TIMING THE DEVELOPMENT OF A DELIVERY SYSTEM

    Dr Paul Gellert

    Dr Paul Gellert, Drug Delivery Project Leader, Product Development, AstraZeneca

  • Stages in the lifecycle of a drug
  • Stages in the lifecycle of drug delivery technology
  • Strategies for drug delivery collaborations
  • Timing of drug delivery activities
  • Advantages of considering drug delivery at an early stage
  • Can it be too early?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Drinks Reception

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Prof Stanley Davis

    Prof Stanley Davis, Scientific Advisor, West Pharmaceutical Services

    9:40 ALZA: INCREASING THE SCOPE OF THE BUSINESS

    Suzanne Martin

    Suzanne Martin, Vice President, Development Programmes, ALZA Corporation

  • Long term business goals at ALZA
  • Effective integration of acquisitions into the company structure
  • Expanding into the post R & D arena
  • Controlling clinical development
  • Advantages of controlling your sales force
  • Impact of expansion on collaborations with the pharmaceutical industry
  • 10:10 INTELLECTUAL PROPERTY RIGHTS

    Nigel Jones

    Nigel Jones, Head of Healthcare Group, Linklaters

  • What forms of right are available?
  • How do I obtain them?
  • How do I enforce them?
  • 10:20 COLLABORATING ON AN INTERNATIONAL SCALE

    Dr Ad van Dooren

    Dr Ad van Dooren, Sales Manager, Banner Pharmacaps

  • The international basis of the pharmaceutical industry
  • An attempt to define ‘culture’
  • Identify potential cultural conflicts
  • Strategies for effective communication across international borders
  • Culture crap or culture gap?
  • 11:00 Morning Coffee

    11:20 NEGOTIATING THE DEAL - MASLOW, EINSTEIN AND SHOE LEATHER

    Duncan Higgons

    Duncan Higgons, Vice President, Business Development, Alkermes

  • Quantitative and qualitative skill sets: do you have them, do you need them?
  • Benchmarking: when to use it and when to throw it away
  • What on earth has Einstein got to do with negotiations?
  • Is business development a euphemism for sales?
  • 12:00 SKYEPHARMA: ACQUISITIONS WITHIN THE DRUG DELIVERY INDUSTRY

    Michael Ashton

    Michael Ashton, Chief Executive Officer, SkyePharma

  • Effective evaluation of your drug delivery portfolio
  • Does it meet the clients’ needs?
  • How well do your technologies complement each other?
  • Identifying suitable technology to acquire and determining the effect on the overall portfolio
  • Co-developing acquired technology with existing drug delivery systems in the portfolio
  • Medac and nanoparticle drug delivery
  • 12:40 Lunch

    13:40 ELAN: THE SOLUTION PROVIDER

    Dr Giovanni Sala

    Dr Giovanni Sala, Director of Licensing, Europe, Elan

  • Developing a portfolio to provide a range of drug delivery solutions
  • Expansion by acquisition and ensuring the whole company benefits from the acquired technology
  • Marketing drug delivery solution provider services
  • Impact of pharmaceutical development at Elan on collaborations with the pharmaceutical industry
  • 14:20 ISSUES IN LICENSING

    Marc Bouiller

    Marc Bouiller, Director Corporate Development & Licensing, Warner Lambert

  • The benefits of licensing drug delivery technology
  • Factors influencing the decision to in-license
  • Challenges in uniting colleagues in support of new drug delivery technology
  • Has the product obtained regulatory approval?
  • Ensuring the infrastructure is in place to deal with the development of licensed drug delivery products
  • 14:20 NOVEN: NEW BUSINESS OPPORTUNITIES

    Sylvia Rossi-Montero

    Sylvia Rossi-Montero, Senior Manager, Business Development, Noven Pharmaceuticals

  • Advantages of transdermals within the drug delivery industry
  • Focus on development using proprietary NCE’s and out-licensing our technologies
  • Expand into non-conventional therapeutic areas with potential markets
  • Identify competitive advantages and target being first to market
  • 15:20 Afternoon Tea

    15:40 MARKET ACCEPTANCE ISSUES

    Vincent Gotz

    Vincent Gotz, Senior Director, Business Development, Dura Pharmaceuticals

  • Rationale for development of drugs in new delivery systems (DDS)
  • Selection of a particular type of drug delivery; Selection of a DDS partner
  • Necessity of gaining acceptance from ‘customers’
  • Define the customer(s); Does the DDS meet their needs?
  • Techniques used in assessment
  • Case study: pulmonary delivery systems (including Spiros)
  • 16:20 PATIENT ACCEPTANCE

    Dr John Siebert

    Dr John Siebert, President & CEO, CIMA

  • Potential market for fast dissolve drug delivery
  • Advantages of fast dissolve drug delivery
  • Not just compliance
  • Patient perception of product; Ease of use
  • Pharmaceutical marketing changes
  • Successful collaborations with pharmaceutical companies
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    The 4P’s of Drug Delivery: Effective Marketing & Branding Strategy
    Workshop

    The 4P’s of Drug Delivery: Effective Marketing & Branding Strategy

    The Hatton, at etc. venues
    7th June 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.